首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Porcine Model of Hemophilia A
Authors:Yuji Kashiwakura  Jun Mimuro  Akira Onishi  Masaki Iwamoto  Seiji Madoiwa  Daiichiro Fuchimoto  Shunichi Suzuki  Misae Suzuki  Shoichiro Sembon  Akira Ishiwata  Atsushi Yasumoto  Asuka Sakata  Tsukasa Ohmori  Michiko Hashimoto  Satoko Yazaki  Yoichi Sakata
Institution:1. Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi-ken, Japan.; 2. Transgenic Animal Research Center, National Institute of Agrobiological Sciences, Tsukuba, Ibaraki-ken, Japan.; 3. Advanced Technology Development Team, Prime Tech Ltd., Tsuchiura, Ibaraki-ken, Japan.; Emory University School of Medicine, United States of America,
Abstract:Hemophilia A is a common X chromosome-linked genetic bleeding disorder caused by abnormalities in the coagulation factor VIII gene (F8). Hemophilia A patients suffer from a bleeding diathesis, such as life-threatening bleeding in the brain and harmful bleeding in joints and muscles. Because it could potentially be cured by gene therapy, subhuman animal models have been sought. Current mouse hemophilia A models generated by gene targeting of the F8 have difficulties to extrapolate human disease due to differences in the coagulation and immune systems between mice and humans. Here, we generated a porcine model of hemophilia A by nuclear transfer cloning from F8-targeted fibroblasts. The hemophilia A pigs showed a severe bleeding tendency upon birth, similar to human severe hemophiliacs, but in contrast to hemophilia A mice which rarely bleed under standard breed conditions. Infusion of human factor VIII was effective in stopping bleeding and reducing the bleeding frequency of a hemophilia A piglet but was blocked by the inhibitor against human factor VIII. These data suggest that the hemophilia A pig is a severe hemophilia A animal model for studying not only hemophilia A gene therapy but also the next generation recombinant coagulation factors, such as recombinant factor VIII variants with a slower clearance rate.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号